EA022219B1 - Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре - Google Patents
Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре Download PDFInfo
- Publication number
- EA022219B1 EA022219B1 EA201270213A EA201270213A EA022219B1 EA 022219 B1 EA022219 B1 EA 022219B1 EA 201270213 A EA201270213 A EA 201270213A EA 201270213 A EA201270213 A EA 201270213A EA 022219 B1 EA022219 B1 EA 022219B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- cell
- virus
- cell culture
- less
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 90
- 241000700605 Viruses Species 0.000 title claims abstract description 71
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 60
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 60
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 44
- 210000004027 cell Anatomy 0.000 claims abstract description 311
- 238000010790 dilution Methods 0.000 claims abstract description 66
- 239000012895 dilution Substances 0.000 claims abstract description 66
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 31
- 238000012258 culturing Methods 0.000 claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 claims abstract description 28
- 230000012010 growth Effects 0.000 claims description 67
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 230000001419 dependent effect Effects 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 16
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 10
- 239000003102 growth factor Substances 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108010023321 Factor VII Proteins 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 229960000182 blood factors Drugs 0.000 claims description 2
- 229940012413 factor vii Drugs 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000010412 perfusion Effects 0.000 abstract description 36
- 230000008901 benefit Effects 0.000 abstract description 11
- 230000014759 maintenance of location Effects 0.000 abstract description 6
- 239000002609 medium Substances 0.000 description 39
- 239000000758 substrate Substances 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000010261 cell growth Effects 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 9
- 238000004114 suspension culture Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 235000012907 honey Nutrition 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000011031 large-scale manufacturing process Methods 0.000 description 5
- 230000000737 periodic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- -1 for example Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012526 feed medium Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 101100453295 Rattus norvegicus Krt12 gene Proteins 0.000 description 1
- 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004720 dielectrophoresis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012716 precipitator Substances 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
- C12M3/006—Cell injection or fusion devices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0056—Xeno-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/98—Xeno-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00051—Methods of production or purification of viral material
- C12N2710/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Sustainable Development (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23031309P | 2009-07-31 | 2009-07-31 | |
| PCT/EP2010/061191 WO2011012725A1 (en) | 2009-07-31 | 2010-08-02 | Method of producing a polypeptide or virus of interest in a continuous cell culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201270213A1 EA201270213A1 (ru) | 2012-06-29 |
| EA022219B1 true EA022219B1 (ru) | 2015-11-30 |
Family
ID=42668436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201270213A EA022219B1 (ru) | 2009-07-31 | 2010-08-02 | Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US8580554B2 (enExample) |
| EP (2) | EP2459697B1 (enExample) |
| JP (2) | JP5808742B2 (enExample) |
| KR (2) | KR101885046B1 (enExample) |
| CN (1) | CN102549142B (enExample) |
| AU (1) | AU2010277490B2 (enExample) |
| BR (1) | BR112012002137B8 (enExample) |
| CA (1) | CA2769354A1 (enExample) |
| CO (1) | CO6491119A2 (enExample) |
| DK (1) | DK2459697T3 (enExample) |
| EA (1) | EA022219B1 (enExample) |
| ES (1) | ES2705206T3 (enExample) |
| HR (1) | HRP20182165T1 (enExample) |
| IN (1) | IN2012DN00899A (enExample) |
| MX (2) | MX2012001274A (enExample) |
| NZ (1) | NZ597742A (enExample) |
| PL (1) | PL2459697T3 (enExample) |
| PT (1) | PT2459697T (enExample) |
| SG (1) | SG178176A1 (enExample) |
| SI (1) | SI2459697T1 (enExample) |
| TR (1) | TR201900213T4 (enExample) |
| WO (1) | WO2011012725A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3037386T3 (en) | 2010-07-08 | 2025-10-01 | Takeda Pharmaceuticals Co | Method of producing recombinant high molecular weight vwf in cell culture |
| ES2890412T3 (es) * | 2011-01-17 | 2022-01-19 | Hoffmann La Roche | Aparato de separación |
| KR101980164B1 (ko) | 2011-05-13 | 2019-05-20 | 옥타파마 아게 | 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법 |
| HUE033279T2 (en) | 2011-07-01 | 2017-11-28 | Amgen Inc | Mammalian cell culture |
| CN203129697U (zh) | 2013-02-05 | 2013-08-14 | 客贝利(厦门)休闲用品有限公司 | 一种帐篷架杆 |
| ES2663815T3 (es) | 2011-11-24 | 2018-04-17 | Genethon | Sistema de producción de un vector lentiviral escalable compatible con aplicaciones farmacéuticas industriales |
| US9574167B2 (en) | 2013-02-15 | 2017-02-21 | Pharyx, Inc. | Methods and apparatus for independent control of product and reactant concentrations |
| HK1219964A1 (zh) | 2013-03-08 | 2017-04-21 | Genzyme Corporation | 治疗性蛋白药物物质的整合连续制造 |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| WO2014146933A1 (en) * | 2013-03-19 | 2014-09-25 | Cmc Biologics A/S | A method for producing a product (e.g. polypeptide) in a continuous cell culture fermentation process. |
| US10392603B2 (en) * | 2013-08-30 | 2019-08-27 | The Chemo-Sero-Therapeutic Research Institute | Method of viral purification |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| TWI671312B (zh) | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
| TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
| AU2015240354A1 (en) | 2014-04-01 | 2016-11-17 | Advantech Bioscience Farmaceutica Ltda. | Stabilization of Factor VIII without calcium as an excipient |
| MX2016012870A (es) | 2014-04-01 | 2017-05-12 | Advantech Bioscience Farmacêutica Ltda | Formulaciones de factor viii estables con bajo tenor de azucar - glicina. |
| EP3158055B1 (en) * | 2014-06-13 | 2019-09-11 | CSL Limited | Improved production of recombinant von willebrand factor in a bioreactor |
| KR20240173213A (ko) | 2016-01-26 | 2024-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 연결된 관류 대 연속-유동식 교반-탱크 반응기 세포 배양 시스템 |
| SG11201809051YA (en) * | 2016-04-15 | 2018-11-29 | Boehringer Ingelheim Int | Cell retention device and method |
| JP7408389B2 (ja) * | 2016-12-21 | 2024-01-05 | エフ． ホフマン－ラ ロシュ アーゲー | 真核細胞の増殖制御方法 |
| IL321253A (en) | 2018-05-01 | 2025-08-01 | Amgen Inc | Antibodies with a modulated glycan profile |
| WO2019239780A1 (ja) * | 2018-06-15 | 2019-12-19 | 富士フイルム株式会社 | 細胞培養方法、細胞培養装置、及び生産物の製造方法 |
| AU2019332764B2 (en) | 2018-08-31 | 2025-05-29 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
| CN113355297A (zh) * | 2021-06-23 | 2021-09-07 | 吉林冠界生物技术有限公司 | 一种灌流式培养全悬浮mdck细胞生产重组禽流感病毒的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019512A (en) | 1989-03-17 | 1991-05-28 | Baxter International Inc. | Spin filter for removing substantially cell-free culture medium from suspension cell culture system |
| US5626734A (en) | 1995-08-18 | 1997-05-06 | University Technologies International, Inc. | Filter for perfusion cultures of animal cells and the like |
| AU2001291653A1 (en) | 2000-10-02 | 2002-04-15 | Novo-Nordisk A/S | Industrial-scale serum-free production of recombinant factor vii in mammalian cells |
| IL161858A0 (en) * | 2001-11-28 | 2005-11-20 | Sandoz Ag | Cell culture process |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| AU2006257073B2 (en) | 2005-06-17 | 2011-08-04 | Children's Medical Center Corporation | ADAMTS13-comprising compositions having thrombolytic activity |
| ES2474573T3 (es) * | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| PL2235197T3 (pl) * | 2007-12-27 | 2018-01-31 | Baxalta GmbH | Sposoby hodowli komórek |
-
2010
- 2010-07-30 US US12/847,921 patent/US8580554B2/en active Active
- 2010-08-02 PT PT10737916T patent/PT2459697T/pt unknown
- 2010-08-02 ES ES10737916T patent/ES2705206T3/es active Active
- 2010-08-02 SG SG2012006599A patent/SG178176A1/en unknown
- 2010-08-02 NZ NZ597742A patent/NZ597742A/en unknown
- 2010-08-02 EA EA201270213A patent/EA022219B1/ru not_active IP Right Cessation
- 2010-08-02 TR TR2019/00213T patent/TR201900213T4/tr unknown
- 2010-08-02 MX MX2012001274A patent/MX2012001274A/es active IP Right Grant
- 2010-08-02 BR BR112012002137A patent/BR112012002137B8/pt active IP Right Grant
- 2010-08-02 KR KR1020177017512A patent/KR101885046B1/ko active Active
- 2010-08-02 KR KR1020127004996A patent/KR101752789B1/ko active Active
- 2010-08-02 SI SI201031835T patent/SI2459697T1/sl unknown
- 2010-08-02 CN CN201080036754.2A patent/CN102549142B/zh active Active
- 2010-08-02 CA CA2769354A patent/CA2769354A1/en not_active Abandoned
- 2010-08-02 AU AU2010277490A patent/AU2010277490B2/en active Active
- 2010-08-02 PL PL10737916T patent/PL2459697T3/pl unknown
- 2010-08-02 HR HRP20182165TT patent/HRP20182165T1/hr unknown
- 2010-08-02 IN IN899DEN2012 patent/IN2012DN00899A/en unknown
- 2010-08-02 JP JP2012522190A patent/JP5808742B2/ja active Active
- 2010-08-02 EP EP10737916.6A patent/EP2459697B1/en active Active
- 2010-08-02 DK DK10737916.6T patent/DK2459697T3/en active
- 2010-08-02 WO PCT/EP2010/061191 patent/WO2011012725A1/en not_active Ceased
- 2010-08-02 EP EP18199855.0A patent/EP3480292A1/en not_active Withdrawn
-
2012
- 2012-01-27 MX MX2014008515A patent/MX353610B/es unknown
- 2012-02-06 CO CO12020130A patent/CO6491119A2/es unknown
-
2013
- 2013-10-10 US US14/050,710 patent/US9650612B2/en active Active
-
2015
- 2015-01-14 JP JP2015004718A patent/JP6177260B2/ja active Active
-
2017
- 2017-04-12 US US15/486,181 patent/US10221400B2/en active Active
-
2019
- 2019-01-18 US US16/252,216 patent/US10745672B2/en active Active
Non-Patent Citations (10)
| Title |
|---|
| ANTOINE G. ET AL. "ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13". BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB LNKD-D0I:10.1046/J.1365-2141.2003.04183.X, vol. 120, no. 5, 1 March 2003 (2003-03-01), pages 821-824, XP002282271, ISSN: 0007-1048, the whole document * |
| BANIK GAUTAM G. ET AL. "Hybridoma growth and antibody production as a function of cell density and specific growth rate in perfusion culture". BIOTECHNOLOGY AND BIOENGINEERING, vol. 48, no. 3, 1995, pages 289-300, XP002599809, ISSN: 0006-3592, the whole document * |
| BATT B.C. ET AL. "INCLINED SEDIMENTATION FOR SELECTIVE RETENTION OF VIABLE HYBRIDOMAS IN A CONTINUOUS SUSPENSION BIOREACTOR". BIOTECHNOLOGY PROGRESS, AMERICAN INSTITUTE OF CHEMICAL ENGINEERS, US LNKD-D0I:10.1021/BP00006A600, vol. 6, 1 January 1990 (1990-01-01), pages 458-464, XP001147277, ISSN: 8756-7938, the whole document * |
| CASTILHO L.R. ET AL. "CELL RETENTION DEVICES FOR SUSPENDED-CELL PERFUSION CULTURES". ADVANCES IN BIOCHEMICAL ENGINEERING, BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 74, 1 January 2002 (2002-01-01), pages 129-169, XP009038515, ISSN: 0724-6145, the whole document * |
| GORENFLO VOLKER M. ET AL. "Optimization of an acoustic cell filter with a novel air-backflush system". BIOTECHNOLOGY PROGRESS, vol. 19, no. 1, January 2003 (2003-01), pages 30-36, XP9138351, ISSN: 8756-7938, the whole document * |
| HILLER G.W. ET AL. "Cell retention-chemostat studies of hybridoma cells: Analysis of hybridoma growth and metabolism in continuous suspension culture on serum-free medium". BIOTECHNOLOGY AND BIOENGINEERING, vol. 42, no. 2, 1993, pages 185-195, XP002599810, ISSN: 0006-3592, the whole document * |
| PLAIMAUER BARBARA ET AL. "Expression and characterization of recombinant human ADAMTS13". SEMINARS IN HEMATOLOGY, vol. 41, no. 1, January 2004 (2004-01), pages 24-33, XP009138417, ISSN: 0037-1963, the whole document * |
| ROBINSON D.K. EP AL. "Effect of specific growth rates on productivity in continuous open and partial cell retention animal cell bioreactors". JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL LNKD-DOI:10.1016/0168-1656(92)90131-R, vol. 22, no. 1-2, 1 January 1992 (1992-01-01), pages 41-50, XP023944261, ISSN: 0168-1656 [retrieved on 1992-01-01], the whole document * |
| SCHMID G. ET AL. "Continuous hybridoma suspension cultures with and without cell retention: kinetics of growth, metabolism and product formation". JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL LNKD-D0I:10.1016/0168-1656(92)90130-2, vol. 22, no. 1-2, 1 January 1992 (1992-01-01), pages 31-40 XP023944260, ISSN: 0168-1656 [retrieved on 1992-01-01], the whole document * |
| VOISARD D. ET AL. "Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells". BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US LNKD-D0I:10.1002/BIT.10629, vol. 82, no. 7, 30 June 2003 (2003-06-30), pages 751-765, XP002317548, ISSN: 0006-3592, tables * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA022219B1 (ru) | Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре | |
| Pilarek et al. | Enhanced plasmid production in miniaturized high-cell-density cultures of Escherichia coli supported with perfluorinated oxygen carrier | |
| JP2025134848A (ja) | 接種物を生産するためのプロセスおよびシステム | |
| KR101980164B1 (ko) | 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법 | |
| Yoon et al. | Effect of culture temperature on follicle-stimulating hormone production by Chinese hamster ovary cells in a perfusion bioreactor | |
| Thyden et al. | Recycling spent animal cell culture media using the thermally resistant microalga Chlorella sorokiniana | |
| CN1772884A (zh) | 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基 | |
| US20160051586A1 (en) | Methods of growing and preparing stem cells and methods of using the same | |
| CN116574671B (zh) | 一种hek293细胞培养基及其应用 | |
| Terashima et al. | Continuous production of human erythropoietin by immobilized recombinant L-929 cells | |
| HK40008436A (en) | Method of producing a polypeptide or virus of interest in a continuous cell culture | |
| CN118667752A (zh) | 一种用于生产人骨形态发生蛋白的细胞培养方法 | |
| HK1169439B (en) | Method of producing a polypeptide or virus of interest in a continuous cell culture | |
| HK1169439A (en) | Method of producing a polypeptide or virus of interest in a continuous cell culture | |
| CN117511860A (zh) | 一种利用生物反应器大规模连续流培养细胞的方法和应用 | |
| PACKED et al. | HIGH CELL DENSITY PERFUSION CULTURE OF HYBRIDOMA CELLS FOR PRODUCTION OF MONOCLONAL ANTIBODIES IN THE CELLIGEN | |
| Baptista et al. | Production of Recombinant Human Leukemia Inhibitory Factor (lif) in a Mammalian Cell Bioreactor: A First Approach | |
| JPH07135968A (ja) | 付着非依存性細胞のマイクロキャリアへの細胞接着方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM |